在患者报告的MDS-UPDRS项目中增加敏感性,用于预测早期PD的药物开始
Haotian Zou1, Christopher G Goetz2, Glenn T Stebbins2
1Department of Biostatistics & Bioinformatics, Duke University, Durham, North Carolina, USA.
Movement disorders clinical practice
|October 18, 2024
概括
一个简洁的六项患者报告规模准确地预测了早期帕金森病 (PD) 中多巴胺激素治疗的开始. 这种"基线结果声音"工具提高了对这一关键临床决定的预测灵敏度.
科学领域:
- 神经学 神经学
- 临床研究 临床研究
- 患者报告的结果
背景情况:
- 运动障碍学会统一的帕金森病评分表 (MDS-UPDRS) 部分IB和II捕捉了帕金森病 (PD) 的患者经验.
- 这些自我报告项目为患者提供了关于疾病进展和治疗需求的宝贵见解.
研究的目的:
- 为了确定MDS-UPDRS部分IB和II项目中最敏感的组合,以预测多巴胺激素治疗的开始.
- 开发一种精细的工具来评估早期PD患者的需求和治疗轨迹.
主要方法:
- 对未经治疗的PD患者进行了长度分析.
- 项目反应理论 (IRT) 和生存分析对患者报告的基线症状的应用.
- 评估20个MDS-UPDRS部分IB和II项目的PD严重程度歧视和信息内容.
主要成果:
- 仅包括第二部分项目在内的六项子集,与全20项量表相比,对多巴胺激素疗法启动的预测准确性更高.
- 这种缩短版本被称为"基线结果语音",显示C指数明显更高 (P=0.001).
结论:
- 六项"基线结果声音"尺度显著提高了在PD早期开始多巴胺治疗的预测.
- 项目响应理论建模有效地完善了现有的措施,以确定关键的预测性患者报告的项目.
- 建议在多种不同人群中进一步验证.
相关概念视频
Parkinson's Disease: Treatment
227
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
227
Parkinson's Disease: Overview
486
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
486
Drug Therapy
39
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
39


